(All fields required)
Please enter a valid email.
Please enter your name.
The Lupus Center at Cincinnati Children's is home to specialists with a wide variety of backgrounds and areas of focus. As a team, this diversity makes us better prepared to care for your child.
Hermine I. Brunner, MD, MSc Director, Division of Rheumatology 513-636-4676 email@example.com
Director, Division of Rheumatology
Professor, UC Department of Pediatrics
Health-related quality of life; outcome research; lupus
MD: Ludwig Maximilan University, Munich, Germany, 1991.
Residency: University of Chicago, 1997.
Fellowship: University of Toronto & Cincinnati, 1999.
MSc: Clinical Epidemiology: University of Toronto, 1999.
Certification: Pediatrics 1997; Rheumatology 2002.
Alexei A. Grom, MD 513-636-3339 firstname.lastname@example.org
The research of Alexei Grom, MD, has mainly involved two translational projects focused on two autoimmune diseases – systemic juvenile rheumatoid arthritis and juvenile dermatomyositis. In both projects, recent advances of cellular immunology are applied to these diseases to promote better understanding of their pathogenesis and treatment.
Systemic onset juvenile rheumatoid arthritis and an associated condition known as macrophage activation syndrome are severe and often devastating illnesses. The pathological mechanisms are not known but Dr. Alexei Grom has focused his research on NK and cytotoxic cell function in this disease. The rationale for this approach has been based on the strong clinical similarities between MAS and the better understood autosomal recessive disorder familial hemophagocytic lymphohistiocytosis, in which the uncontrolled proliferation of T cells and macrophages has been recently associated with decreased NK cell and cytotoxic cell functions secondary to mutations in the gene encoding perforin. Recent observations suggest as in FHLH, MAS patients also have profoundly depressed NK function. Moreover, a large subgroup of systemic JRA patients has very similar immunologic abnormalities. Combined with the evidence of the immunoregulatory role of NK cells in many immune responses, this suggests that NK dysfunction is relevant to the pathogenesis of MAS. New directions have thus been established for research in this poorly understood disease.
Juvenile dermatomyositis is a chronic inflammatory condition involving primarily muscles and skin. The most characteristic feature of JDM is vascular damage associated with the capillary necrosis that eventually leads to capillary loss and tissue ischemia. The project is based on the hypothesis that capillary loss in this condition may be caused by angiostatic chemokines that are prominent in the inflammatory response in the affected muscles.
De Benedetti F, Brunner HI, Ruperto N, Kenwright, A, Ravelli A, Schneider, Woo P, Wouters C, Zemel, L, Burgos-Vargos R, Dolezalova P, Grom AA, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A. Tocilizumab in systemic juvenile idiopathic arthritis: a randomized trial. New Engl J Med. 367:2385-95. 2012.
Sikora KA, Fall N, Thornton S and Grom AA. A Markedly Low-Level of Interferon-Induced Gene Expression Distinguishes Active Systemic Juvenile Idiopathic Arthritis Synovium From other JIA subtypes: Implications for Pathogenesis of Macrophage Activation Syndrome. Arthritis Rheum. 64:3799-808. 2012.
Ruperto N, Brunner HI, Quartier P, Constantin T, Wulfraat N, Horneff G, Brik R, McCann L, Nistala K, Wouters C, Cimaz R, Ferrandiz MA, Flato B, Grom AA, Magnusson, Ozen S, Abrams K, Kim D, Martini A, Lovell DJ. Canakinumab in systemic juvenile arthritis with active systemic features. New Engl J Med. 367:2396-406. 2012.
Mellins ED, Macubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nature Reviews Rheumatology. 7:416-26. 2011.
Sumegi J, Barnes MG, Lee S, Villanueva J, Zhang K, Nestheide SV, Risma K, Grom AA, AH Filipovich. Gene Expression Profiling of peripheral blood mononuclear cells from patients with untreated familial hemophagocytic lymphohistiocytosis. Blood. 117:151-60. 2011.
Barnes MG, Grom AA, Thompson SD, Griffin TA, Luyrink LK, Colbert, RA, David N, Glass DN. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 2010.
Hinze CH, Fall N, Thornton S, Griffin TA, Thompson SD, Colbert RA, Glass DN, Michael G, Barnes BG, Grom AA. Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis. Arthritis Res Ther. 2010.
Barnes MG, Grom AA, Thompson SD, Ilowite NT, Olson JC, Sherry DD, Gottlieb BS, Aronow BJ, Pavlidis P, Hinze C, Thornton S, Griffin TA, Colbert CA, DN Glass. Gene Expression Signatures in new onset untreated juvenile idiopathic arthritis. Arthritis Rheum. 60:2102-12. 2009.
Zhang K, Biroscak J, Glass DN, Thompson S, Finkel T, Murray P, Binstadt B, Filipovich A, Grom AA. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13D polymorphisms. Arthritis Rheum. x58:2892-6. 2008.
Fall N, Barnes M, Thornton S, Luyrink L, Olson J, Ilowite NT, Gottlieb E, Griffin T, Sherry DD, Thompson S, Glass DN, Colbert RA, Grom AA. Gene expression profiling in peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome. Arthritis Rheum. 56:3793-804. 2007.
Jennifer L. Huggins, MD Fellowship Program Director, Division of Rheumatology 513-803-0649 email@example.com
Fellowship Program Director, Division of Rheumatology
Associate Professor, UC Department of Pediatrics
Huggins JL, Coca A, Bundy, KW, Marston B, Looney RJ. Macrophage Activation Syndrome: Serological Markers and Treatment with Anti-Thymocyte Globulin. Clinical Immunology. 2009 132(1):10-18.
Huggins JL, Sanz I et al. Cellular Origin of Autoantibodies in Systemic Lupus Erythematosus. A&R. 2007 56:S1427. Huggins JL, Sanz I, Zand M et al. CpG DNA Activation and Plasma Cell Differentiation of CD27- Naïve Human B Cells. Blood. 2007109:1611-1619. Huggins, JL, Brunner HI. Targeting B Cell in the Treatment of Childhood-Onset Systemic Lupus Erythematosus. Journal of Pediatrics 2006;148:571-3. Zand M, Sanz I, Huggins J et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood. 2006 107:2895-2903. Huggins JL, Sanz I, Zand M et al. Differential Requirements of Naïve Peripheral Blood B Cells for Activation by CpG DNA. Annals of Rheumatic Diseases. 2006. Looney RL, Huggins JL. Use of Intravenous Immunoglobulin G (IVIG). Bailliere’s Best Practice in Clinical Haematology. 2006 19:3-27. Zand, M, Vo T, Huggins J, et al. Polyclonal Rabbit Antithymocyte Globulin Triggers B-Cell and Plasma Cell Apoptosis by Multiple Pathways. Transplantation. 2005 79:1507-1515. Huggins JL, Sanz I, Zand M. CpG DNA Induces Plasma Cell Differentiation of Naïve CD27- Human B Cells. A&R. 2004 50:S227. Huggins JL, Sanz I, Zand M. CpG DNA Induces Plasma Cell Differentiation of Naïve CD27- Human B Cells. Clinical and Investigative Medicine. 2004 27.
Daniel J. Lovell, MD, MPH Associate Director, Division of Rheumatology 513-636-4676 firstname.lastname@example.org
Associate Director, Division of Rheumatology
Diagnostic evaluation and ongoing care of children with all pediatric onset rheumatic diseases
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6.
Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Chon Y, Zhang N, Baumgartner SW. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2010 Nov;62(11):3259-64.
Giannini EH, Ilowite NT, Lovell DJ, Wallace CA, Rabinovich CE, Reiff A, Higgins G, Gottlieb B, Singer NG, Chon Y, Lin SL, Baumgartner SW; Pediatric Rheumatology Collaborative Study Group. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum. 2009 Sep;60(9):2794-804.
Seid M, Opipari L, Huang B, Brunner HI, Lovell DJ. Disease control and health-related quality of life in juvenile idiopathic arthritis. Arthritis Rheum. 2009 Mar 15;61(3):393-9.
Carrasco R, Lovell DJ, Giannini EH, Henderson CJ, Huang B, Kramer S, Ranz J, Heubi J, Glass D. Biochemical markers of bone turnover associated with calcium supplementation in children with juvenile rheumatoid arthritis: results of a double-blind, placebo-controlled intervention trial. Arthritis Rheum. 2008 Dec;58(12):3932-40.
Lovell DJ, Ruperto N, Goodman S, Reiff A, Jung L, Jarosova K, Nemcova D, Mouy R, Sandborg C, Bohnsack J, Elewaut D, Foeldvari I, Gerloni V, Rovensky J, Minden K, Vehe RK, Weiner LW, Horneff G, Huppertz HI, Olson NY, Medich JR, Carcereri-De-Prati R, McIlraith MJ, Giannini EH, Martini A; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008 Aug 21;359(8):810-20.
Ting TV, Lovell DJ. Does early sulfasalazine treatment provide long-term benefits to patients with juvenile idiopathic arthritis? Nat Clin Pract Rheumatol. 2008 Jul;4(7):344-5.
Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, Baumgartner SW, Giannini EH; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008 May;58(5):1496-504.
Shishov M, Henrickson M, Burgos-Vargas R, Rubio-Pérez N, Baca V, Romero-Feregrino R, Solís-Vallejo E, Huang B, Grom AA, Lovell DJ. Systemic features and early prognostic factors in Hispanic and non-Hispanic children from the United States of America and Mexico with systemic juvenile idiopathic arthritis. Clin Exp Rheumatol. 2007 Nov-Dec;25(6):907-14.
Lovell DJ. Update on treatment of arthritis in children: new treatments, new goals. Bull NYU Hosp Jt Dis. 2006;64(1-2):72-6. Review.
Prasad Devarajan, MD Director, Division of Nephrology and Hypertension 513-636-4531 email@example.com
Director, Division of Nephrology and Hypertension
Medical Director, Stone Center
Director, Nephrology and Hypertension Clinical Laboratory
Louise M. Williams Endowed Chair
Clinical specialties: Acute kidney injury, nephrotic syndrome, kidney stones
Visit the Devarajan Lab.
Czech KA, Bennett M, Devarajan P. Distinct metalloproteinase excretion patterns in focal segmental glomerulosclerosis. Pediatr Nephrol. 2011 Jul 1.
Askenazi DJ, Koralkar R, Levitan EB, Goldstein SL, Devarajan P, Khandrika S, Mehta RL, Ambalavanan N. Baseline Values of Candidate Urine Acute Kidney Injury (AKI) Biomarkers Vary by Gestational Age in Premature Infants. Pediatr Res. 2011 Jun 3. Abraham BP, Frazier EA, Morrow WR, Blaszak RT, Devarajan P, Mitsnefes M, Bryant JC, Sachdeva R. Cystatin C and neutrophil gelatinase-associated lipocalin as markers of renal function in pediatric heart transplant recipients. Pediatr Transplant. 2011 Apr 25. Sundaram N, Bennett M, Wilhelm J, Kim MO, Atweh G, Devarajan P, Malik P. Biomarkers for early detection of sickle nephropathy. Am J Hematol. 2011 Jul;86(7):559-66. Devarajan P, Krawczeski C. In reply to 'antifibrinolytic use during cardiac and hepatic surgery makes tubular proteinuria-based early biomarkers poor tools to diagnose perioperative acute kidney injury'. Am J Kidney Dis. 2011 Jun;57(6):960-1. Piyaphanee N, Ma Q, Kremen O, Czech K, Greis K, Mitsnefes M, Devarajan P, Bennett MR. Discovery and initial validation of α 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clin Appl. 2011 Jun;5(5-6):334-42.
Li S, Krawczeski CD, Zappitelli M, Devarajan P, Thiessen-Philbrook H, Coca SG, Kim RW, Parikh CR; for the TRIBE-AKI Consortium. Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study. Crit Care Med. 2011 Jun;39(6):1493-1499. Krawczeski CD, Woo JG, Wang Y, Bennett MR, Ma Q, Devarajan P. Neutrophil gelatinase-associated lipocalin concentrations predict development of acute kidney injury in neonates and children after cardiopulmonary bypass. J Pediatr. 2011 Jun;158(6):1009-1015.e1.
Basu RK, Devarajan P, Wong H, Wheeler DS. An update and review of acute kidney injury in pediatrics. Pediatr Crit Care Med. 2011 May;12(3):339-47.
Devarajan P. Biomarkers for the early detection of acute kidney injury. Curr Opin Pediatr. 2011 Apr;23(2):194-200.
Jens W. Goebel, MD Clinical Director, Nephrology and Hypertension 513-636-4531 firstname.lastname@example.org
Clinical Director, Nephrology and Hypertension
Medical Director, Kidney Transplantation
Clinical Director, Kidney Transplantation
Organ transplantation in children
Sanchez-Pinto LN, Laskin BL, Jodele S, Hummel TR, Yin HJ, Goebel J. BK virus nephropathy in a pediatric autologous stem-cell transplant recipient. Pediatr Blood Cancer. 2011 Mar;56(3):495-7. Hooper DK, Carle AC, Schuchter J, Goebel J. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant. 2011 Feb;15(1):88-95. Sherwin CM, Fukuda T, Brunner HI, Goebel J, Vinks AA. The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan 1;50(1):1-24.Campbell K, Ng V, Martin S, Magee J, Goebel J, Anand R, Martz K, Bucuvalas J; SPLIT Renal Function Working Group. Glomerular filtration rate following pediatric liver transplantation--the SPLIT experience. Am J Transplant. 2010 Dec;10(12):2673-82. Pai AL, Gray E, Kurivial K, Ross J, Schoborg D, Goebel J. The Allocation of Treatment Responsibility scale: a novel tool for assessing patient and caregiver management of pediatric medical treatment regimens. Pediatr Transplant. 2010 Dec;14(8):993-9.Jodele S, Bleesing JJ, Mehta PA, Filipovich AH, Laskin BL, Goebel J, Pinkard SL, Davies SM. Successful early intervention for hyperacute transplant-associated thrombotic microangiopathy following pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2010 Nov 5. Pai AL, Ingerski LM, Perazzo L, Ramey C, Bonner M, Goebel J. Preparing for transition? The allocation of oral medication regimen tasks in adolescents with renal transplants. Pediatr Transplant. 2011 Feb;15(1):9-16. Laskin BL, Goebel J, Davies SM, Khoury JC, Bleesing JJ, Mehta PA, Filipovich AH, Paff ZN, Lawrence JM, Yin HJ, Pinkard SL, Jodele S. Early clinical indicators of transplant-associated thrombotic microangiopathy in pediatric neuroblastoma patients undergoing auto-SCT. Bone Marrow Transplant. 2010 Aug 9.
Herzer M, Goebel J, Cortina S. Transitioning cognitively impaired young patients with special health needs to adult-oriented care: collaboration between medical providers and pediatric psychologists. Curr Opin Pediatr. 2010 Oct;22(5):668-72.
Fukuda T, Goebel J, Thøgersen H, Maseck D, Cox S, Logan B, Sherbotie J, Seikaly M, Vinks AA. Inosine Monophosphate Dehydrogenase (IMPDH) Activity as a Pharmacodynamic Biomarker of Mycophenolic Acid Effects in Pediatric Kidney Transplant Recipients. J Clin Pharmacol. 2010 Apr 23.
Alexander A. Vinks, PharmD, PhD, FCP Director, Division of Clinical Pharmacology 513-636-0159 email@example.com
Director, Division of Clinical Pharmacology
Scientific Director, Pharmacy Research, Research in Patient Services
Adjunct Professor of Pharmacology
Sander Vinks, PharmD, PhD, FCP, is a professor of Pediatrics and Pharmacology at the University of Cincinnati, College of Medicine. He is the director of the Division of Clinical Pharmacology, and serves as director of the Pediatric Clinical and Developmental Pharmacology NIH T32 training program since 2011. He is co-director of Cincinnati Children’s Genetic Pharmacology Service, and Scientific Director for Pharmacy Research in the Division of Patient Services. He also directs the Laboratory of Applied Pharmacokinetics and Pharmacogenetics (LAPP) and a multidisciplinary Pharmacometrics Core. Dr. Vinks also serves as an advisor on an FDA pediatric sub-committee.
Dr. Vinks is the past president of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. He serves on the Board of Regents of the American College of Clinical Pharmacology and is chair of the Clinical Pharmacology and Translational Research committee of the American Association of Pharmaceutical Scientists. He has served as the principal investigator of the former NICHD Pediatric Research Unit at Cincinnati Children’s Hospital Medical Center.
His major research interests include personalized and precision medicine, pharmacokinetic-pharmacodynamic (PK/PD) modeling, physiologically based pharmacokinetics (PBPK), pharmacogenetics/genomics (PG) and the application of genomic, population and simulation approaches (Pharmacometrics) to pediatric trial design and Therapeutic Drug Management.
Dr. Vinks has presented his research as an invited speaker in 220 national and international conferences, has published over 140 peer reviewed manuscripts and 18 book chapters and has presented more than 150 abstracts. He is associate editor of Clinical Pharmacology & Therapeutics. Dr. Vinks is both board certified in clinical pharmacology and toxicology and is a fellow of the American College of Clinical Pharmacology.
Certification: American Board of Clinical Pharmacology, 2001.
PhD: Clinical Pharmacology, Leiden University, Leiden The Netherlands, 1996.
PharmD: Hospital Pharmacy, The Hague Central Hospital Pharmacy, The Hague, The Netherlands, 1986.
MS: Pharmacology, University of Toronto, Toronto Canada, 1983.
MS: Pharmacy, Leiden University, Leiden, The Netherlands, 1981.
Wiles JR, Isemann B, Ward LP, Vinks AA, Akinbi H. Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure. J Pediatr. 2014 Sep;165(3):440-6.
Hahn A, Frenck RW Jr, Zou Y, Vinks AA. Validation of a Pediatric Population Pharmacokinetic Model for Vancomycin. Ther Drug Monit. 2014 Nov 21.
Nehus EJ, Mouksassi S, Vinks AA, Goldstein S. Meropenem in Children Receiving Continuous Renal Replacement Therapy: Clinical Trial Simulations Using Realistic Covariates. Journal Clin Pharmacology. 2014 Dec;54(12):1421-1428.
Smits TA, Cox S, Fukuda T, Sherbotie JR, Ward RM, Goebel J, Vinks AA. Effects of unbound mycophenolic Acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. Ther Drug Monit. 2014 Dec;36(6):716-23.
Dong M, Fukuda T, Cox S, de Vries MT, Hooper DK, Goebel J, Vinks AA. Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Br J Clin Pharmacol. 2014 Nov;78(5):1102-12.
Rasmussen-Torvik LJ, Stallings SC, Gordon AS, et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin Pharmacol Ther. 2014 Oct;96(4):482-9.
Emoto C, Fukuda T, Mizuno T, Cox S, Schniedewind B, Christians U, Widemann BC, Fisher MJ, Weiss B, Perentesis J, Vinks AA. Age dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Ther Drug Monitoring. 2014 Aug 26.
Venkatasubramanian R, Fukuda T, Niu J, Mizuno T, Chidambaran V, Vinks AA, Sadhasivam S. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics. 2014 Jul;15(10):1297-309.
Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL; on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases. Individualized antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498-509.
Janalee Taylor, MSN, APRN, CNS Associate Clinical Director 513-636-4676 firstname.lastname@example.org
Associate Clinical Director
Nurse Pracitioner, Division of Rheumatology
Care of children with pediatric rheumatic diseases; self-management and patient education; quality improvement and patient outcomes
Lovell DJ, Passo MH, Beukelman T, Bowyer SL, Gottlieb BS, Henrickson M, Ilowite NT, Kimura Y, DeWitt EM, Segerman J, Stein LD, Taylor J, Vehe RK, Giannini EH. Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):10-6. Kocharla L, Taylor J, Weiler T, Ting TV, Luggen M, Brunner HI. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol. 2009 Dec;36(12):2813-8.
Passo MH, Taylor J. Quality improvement in pediatric rheumatology: what do we need to do? Curr Opin Rheumatol. 2008 Sep;20(5):625-30. Review. Brunner HI, Taylor J, Britto MT, Corcoran MS, Kramer SL, Melson PG, Kotagal UR, Graham TB, Passo MH. Differences in disease outcomes between medicaid and privately insured children: possible health disparities in juvenile rheumatoid arthritis. Arthritis Rheum. 2006 Jun 15;55(3):378-84.
Barron AC, Lee TL, Taylor J, Moore T, Passo MH, Graham TB, Griffin TA, Grom AA, Lovell DJ, Brunner HI. Feasibility and construct validity of the parent willingness-to-pay technique for children with juvenile idiopathic arthritis. Arthritis Rheum. 2004 Dec 15;51(6):899-908. Gerhardt CA, Vannatta K, McKellop JM, Taylor J, Passo M, Reiter-Purtill J, Zeller M, Noll RB. Brief report: child-rearing practices of caregivers with and without a child with juvenile rheumatoid arthritis: perspectives of caregivers and professionals. J Pediatr Psychol. 2003 Jun;28(4):275-9.
Gerhardt CA, Vannatta K, McKellop JM, Zeller M, Taylor J, Passo M, Noll RB. Comparing parental distress, family functioning, and the role of social support for caregivers with and without a child with juvenile rheumatoid arthritis. J Pediatr Psychol. 2003 Jan-Feb;28(1):5-15.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY: 1-513-636-4900
New to Cincinnati Children’s or live outside of the Tristate area? 1-877-881-8479
© 1999-2015 Cincinnati Children's Hospital Medical Center